Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cytokine therapy for hematological malignancies

¹Department of Internal Medicine, Fujita Health University, School of Medicine, Aichi, Japan.

International Journal of Hematology

|December 1, 1996

Summary

Interferon-alpha is a key cytokine therapy for hematological malignancies, showing significant results in chronic myelogenous leukemia. Colony-stimulating factors effectively reduce neutropenia and improve recovery after chemotherapy or transplantation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].

Gan to kagaku ryoho. Cancer & chemotherapy·2001

Same author

Immunohistologic localization of estrone sulfatase in uterine endometrium and adenomyosis.

Obstetrics and gynecology·2001

Same author

Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis.

Clinica chimica acta; international journal of clinical chemistry·2001

Same author

Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease.

Clinica chimica acta; international journal of clinical chemistry·2000

Same author

Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia.

Gan to kagaku ryoho. Cancer & chemotherapy·2000

Same author

[Retrospective study of acute myelogenous leukemia in 83 elderly patients: clinical and biological characteristics].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2000

Area of Science:

Oncology
Hematology
Immunology

Background:

Cytokines are increasingly used in treating hematological malignancies.
Interferon (IFN) and colony-stimulating factors (CSFs) are prominent examples.

Purpose of the Study:

To review the therapeutic roles and mechanisms of IFN-alpha and CSFs in hematological cancers.
To highlight the clinical efficacy and future potential of these biological response modifiers.

Main Methods:

Review of clinical data and studies on Interferon-alpha therapy.
Analysis of research on Granulocyte (G)- and Granulocyte-Macrophage (GM)-CSF in cancer treatment.

Main Results:

IFN-alpha is approved for chronic myelogenous leukemia, multiple myeloma, and hairy cell leukemia, with significant cytogenetic responses in CML.
CSFs effectively reduce neutropenia, infection rates, and hospitalization in patients undergoing chemotherapy or stem cell transplantation.
CSFs aid in peripheral blood stem cell mobilization and increasing chemotherapy dose intensity, though priming leukemic cells remains investigational.

Conclusions:

IFN-alpha is a versatile antitumor agent in hematological malignancies, offering long-term survival benefits, especially in CML.
CSFs are crucial for supportive care in cancer therapy, enhancing neutrophil recovery and treatment tolerance.
Further research into IFN's antitumor mechanisms could revolutionize cancer treatment strategies.

Related Experiment Videos